Long Non-Coding RNAs (lncRNA) Are Key Factors in the Complex Puzzle of Breast Cancer Immunopathogenesis: A Review Study
-
Mohammad Lotfi
,
Mohammad-Reza Mahmoudian-Sani
,
Mohammad Saeedi-Sarqaleh
,
Fatemeh Shojaei-Moghaddam
,
Haniyeh Saadati-Maleki
,
Elaheh Karimzadeh-Soureshjani
,
Rasoul Saadi
,
Ali Saeedi-Boroujeni
Abstract
Long non-coding RNAs (LnC RNAs) exert a substantial influence on breast cancer by exerting both positive and negative control over signaling pathways. LncRNAs are transcribed similarly to mRNA, however they do not undergo the process of translation to become proteins. Initially, these RNAs were classified as "Junk RNAs" since they were thought to lack any practical use. Comprehensive research has demonstrated that they play a vital role in the progression of various diseases, including malignancies, allergies, autoimmune and autoinflammatory disorders, infectious diseases, cardiovascular disease, and atherosclerosis. Despite multiple efforts, breast cancer continues to be a substantial concern and is one of the most prevalent forms of malignancy, especially among women. Recently, researchers have been dedicated to acquiring a deeper understanding of how complex signaling pathways are controlled by Lnc-RNAs in breast cancer. In the setting of breast cancer, Lnc-RNAs have a contradictory effect. The objective of this study is to Review and categorize previous studies An investigation was conducted to examine the impact of long non-coding RNAs on breast cancer. This will improve the capacity to identify topics of research that require further investigation in future studies.
1. Lawrence RA. Anatomy of the Breast. Breastfeeding: Elsevier; 2022. p. 38-57.
2. Ellis H, Mahadevan V. Anatomy and physiology of the breast. Surgery (Oxford). 2013;31(1):11-14.
3. Starek-Swiechowicz B, Budziszewska B, Starek A. Alcohol and breast cancer. Pharmacol Rep. 2023;75(1):69-84.
4. Van Baelen K, Geukens T, Maetens M, Tjan-Heijnen V, Lord CJ, Linn S, et al. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Ann Oncol. 2022;33(8):769-85.
5. Dastjerd NT, Valibeik A, Rahimi Monfared S, Goodarzi G, Moradi Sarabi M, Hajabdollahi F, et al. Gene therapy: A promising approach for breast cancer treatment. Cell Biochem Funct. 2022;40(1):28-48.
6. Kesheh MM, Mahmoudvand S, Shokri S. Long noncoding RNAs in respiratory viruses: A review. Rev Med Virol. 2022;32(2):e2275.
7. Zhu P, Liu B, Fan Z. Noncoding RNAs in tumorigenesis and tumor therapy. Fundam Res. 2023;3(5):692-706.
8. Hu J, Peng F, Qiu X, Yang J, Li J, Shen C, et al. NR2F1-AS1: A Functional Long Noncoding RNA in Tumorigenesis. Curr Med Chem. 2023;30(37):4266-76.
9. Song J, Tang Y, Song F. Lnc‑RGS5 sponges miR‑542‑5p to promote FoxM1/VEGFA signaling and breast cancer cell proliferation. Int J Oncol. 2023;63(4).
10. Yang M, Lu Y, Piao W, Jin H. The Translational Regulation in mTOR Pathway. Biomolecules. 2022;12(6):802.
11. Li J, Zhang J, Jin L, Deng H, Wu J. Silencing lnc-ASAH2B-2 Inhibits Breast Cancer Cell Growth via the mTOR Pathway. Anticancer Res. 2018;38(6):3427-34.
12. Lee JH, Massague J. TGF-beta in developmental and fibrogenic EMTs. Semin Cancer Biol. 2022;86(Pt 2):136-45.
13. Yu XY, Sun Q, Zhang YM, Zou L, Zhao YY. TGF-beta/Smad Signaling Pathway in Tubulointerstitial Fibrosis. Front Pharmacol. 2022;13:860588.
14. Li Z, Dong M, Fan D, Hou P, Li H, Liu L, et al. LncRNA ANCR down-regulation promotes TGF-beta-induced EMT and metastasis in breast cancer. Oncotarget. 2017;8(40):67329-43.
15. Wu ZJ, Li Y, Wu YZ, Wang Y, Nian WQ, Wang LL, et al. Long non-coding RNA CCAT2 promotes the breast cancer growth and metastasis by regulating TGF-beta signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(4):706-14.
16. Pourramezan Z, Attar FA, Yusefpour M, Azizi M, Oloomi M. Circulating LncRNAs landscape as potential biomarkers in breast cancer. Cancer Rep (Hoboken). 2023;6(2):e1722.
17. Li J, Huang Y, Deng X, Luo M, Wang X, Hu H, et al. Long noncoding RNA H19 promotes transforming growth factor-beta-induced epithelial-mesenchymal transition by acting as a competing endogenous RNA of miR-370-3p in ovarian cancer cells. Onco Targets Ther. 2018;11:427-40.
18. Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, et al. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015;6(30):29209-23.
19. Richards EJ, Zhang G, Li ZP, Permuth-Wey J, Challa S, Li Y, et al. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) beta: LncRNA-hit-mediated TGFbeta-induced epithelial to mesenchymal transition in mammary epithelia. J Biol Chem. 2015;290(11):6857-67.
20. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015;6(13):11652-63.
21. Rim EY, Clevers H, Nusse R. The Wnt Pathway: From Signaling Mechanisms to Synthetic Modulators. Annu Rev Biochem. 2022;91:571-98.
22. Xiao C, Wu CH, Hu HZ. LncRNA UCA1 promotes epithelial-mesenchymal transition (EMT) of breast cancer cells via enhancing Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2016;20(13):2819-24.
23. Huan J, Xing L, Lin Q, Xui H, Qin X. Long noncoding RNA CRNDE activates Wnt/beta-catenin signaling pathway through acting as a molecular sponge of microRNA-136 in human breast cancer. Am J Transl Res. 2017;9(4):1977-89.
24. Cai Y, He J, Zhang D. Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. Onco Targets Ther. 2015;8:2657-64.
25. Li X, Yang J, Ni R, Chen J, Zhou Y, Song H, et al. Hypoxia-induced lncRNA RBM5-AS1 promotes tumorigenesis via activating Wnt/beta-catenin signaling in breast cancer. Cell Death Dis. 2022;13(2):95.
26. Li FL, Guan KL. The two sides of Hippo pathway in cancer. Semin Cancer Biol. 2022;85:33-42.
27. Wang M, Dai M, Wang D, Tang T, Xiong F, Xiang B, et al. The long noncoding RNA AATBC promotes breast cancer migration and invasion by interacting with YBX1 and activating the YAP1/Hippo signaling pathway. Cancer Lett. 2021;512:60-72.
28. Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, et al. The JAK-STAT pathway at 30: Much learned, much more to do. Cell. 2022;185(21):3857-76.
29. Hjazi A, Obaid RF, Ali SS, Abdullaev B, Alsaab HO, Huldani H, et al. The cross-talk between LncRNAs and JAK-STAT signaling pathway in cancer. Pathol Res Pract. 2023;248:154657.
30. Zhang Y, Li Z, Chen M, Chen H, Zhong Q, Liang L, et al. lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer. Breast Cancer. 2020;27(4):573-85.
31. Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017;127(12):4498-515.
32. Chisholm KM, Wan Y, Li R, Montgomery KD, Chang HY, West RB. Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma. PLoS One. 2012;7(10):e47998.
33. Shi Y, Huang Q, Kong X, Zhao R, Chen X, Zhai Y, et al. Current Knowledge of Long Non-Coding RNA HOTAIR in Breast Cancer Progression and Its Application. Life (Basel). 2021;11(6).
34. Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, et al. MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells. 2014;32(11):2858-68.
35. Asadi M, Taghizadeh S, Kaviani E, Vakili O, Taheri-Anganeh M, Tahamtan M, et al. Caspase-3: Structure, function, and biotechnological aspects. Biotechnol Appl Biochem. 2022;69(4):1633-45.
36. Chen DQ, Zheng XD, Cao Y, He XD, Nian WQ, Zeng XH, et al. Long non-coding RNA LINC00628 suppresses the growth and metastasis and promotes cell apoptosis in breast cancer. Eur Rev Med Pharmacol Sci. 2017;21(2):275-83.
37. Li T, Liu Y, Xiao H, Xu G. Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer. Breast Cancer. 2017;24(4):535-43.
38. Liao XH, Wang JG, Li LY, Zhou DM, Ren KH, Jin YT, et al. Long intergenic non-coding RNA APOC1P1-3 inhibits apoptosis by decreasing alpha-tubulin acetylation in breast cancer. Cell Death Dis. 2016;7(5):e2236.
39. Jandick NA, Kirner N, Miller CL. Mammalian orthoreovirus infection in human epidermal growth factor receptor 2 positive (HER2+) breast cancer cells. bioRxiv. 2023:2023.05. 10.540250.
40. Sas‐Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, et al. LIMT is a novel metastasis inhibiting lnc RNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO molecular medicine. 2016;8(9):1052-64.
41. Schlein LJ, Thamm DH. Review: NF-kB activation in canine cancer. Vet Pathol. 2022;59(5):724-32.
42. Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, et al. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015;27(3):370-81.
43. Marvalim C, Datta A, Lee SC. Role of p53 in breast cancer progression: An insight into p53 targeted therapy. Theranostics. 2023;13(4):1421-42.
44. Yu Y, Lv F, Liang D, Yang Q, Zhang B, Lin H, et al. HOTAIR may regulate proliferation, apoptosis, migration and invasion of MCF-7 cells through regulating the P53/Akt/JNK signaling pathway. Biomed Pharmacother. 2017;90:555-61.
45. Liang Y, Li Y, Song X, Zhang N, Sang Y, Zhang H, et al. Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. Cancer Biol Ther. 2018;19(2):120-31.
46. Chen R, Liu Y, Zhuang H, Yang B, Hei K, Xiao M, et al. Quantitative proteomics reveals that long non-coding RNA MALAT1 interacts with DBC1 to regulate p53 acetylation. Nucleic Acids Res. 2017;45(17):9947-59.
47. Cerma K, Piacentini F, Moscetti L, Barbolini M, Canino F, Tornincasa A, et al. Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. Biomedicines. 2023;11(1).
48. Zhang CY, Yu MS, Li X, Zhang Z, Han CR, Yan B. Overexpression of long non-coding RNA MEG3 suppresses breast cancer cell proliferation, invasion, and angiogenesis through AKT pathway. Tumour Biol. 2017;39(6):1010428317701311.
49. Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang G, et al. Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. Int J Clin Exp Pathol. 2015;8(5):4881-91.
50. Chen S, Wang Y, Zhang JH, Xia QJ, Sun Q, Li ZK, et al. Long non-coding RNA PTENP1 inhibits proliferation and migration of breast cancer cells via AKT and MAPK signaling pathways. Oncol Lett. 2017;14(4):4659-62.
51. Zhan XJ, Wang R, Kuang XR, Zhou JY, Hu XL. Elevated expression of myosin VI contributes to breast cancer progression via MAPK/ERK signaling pathway. Cell Signal. 2023;106:110633.
52. Peng WX, Huang JG, Yang L, Gong AH, Mo YY. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer. Mol Cancer. 2017;16(1):161.
53. Wang L, Li J, Zhao H, Hu J, Ping Y, Li F, et al. Identifying the crosstalk of dysfunctional pathways mediated by lncRNAs in breast cancer subtypes. Mol Biosyst. 2016;12(3):711-20.
54. Gao FY, Li XT, Xu K, Wang RT, Guan XX. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun Signal. 2023;21(1):28.
55. Mirmazhari SP, Abdi MJ, Mosadeghrad AH, Bonab RA, Babadi AA, Rigi G, et al. Unraveling the Complex Interplay between lncRNAs and Myc in Breast Cancer. 2023.
56. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, et al. lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. Cancer cell. 2018;33(4):706-20. e9.
57. Wang O, Yang F, Liu Y, Lv L, Ma R, Chen C, et al. C-MYC-induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer. Am J Transl Res. 2017;9(2):533-45.
58. Tamang S, Acharya V, Roy D, Sharma R, Aryaa A, Sharma U, et al. SNHG12: An LncRNA as a Potential Therapeutic Target and Biomarker for Human Cancer. Front Oncol. 2019;9:901.
59. Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35(21):2746-55.
60. Wang S, Ke H, Zhang H, Ma Y, Ao L, Zou L, et al. LncRNA MIR100HG promotes cell proliferation in triple-negative breast cancer through triplex formation with p27 loci. Cell Death Dis. 2018;9(8):805.
61. Wood JL, Zhang C, Mathews ER, Tang C, Franks AE. Microbial community dynamics in the rhizosphere of a cadmium hyper-accumulator. Sci Rep. 2016;6:36067.
2. Ellis H, Mahadevan V. Anatomy and physiology of the breast. Surgery (Oxford). 2013;31(1):11-14.
3. Starek-Swiechowicz B, Budziszewska B, Starek A. Alcohol and breast cancer. Pharmacol Rep. 2023;75(1):69-84.
4. Van Baelen K, Geukens T, Maetens M, Tjan-Heijnen V, Lord CJ, Linn S, et al. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Ann Oncol. 2022;33(8):769-85.
5. Dastjerd NT, Valibeik A, Rahimi Monfared S, Goodarzi G, Moradi Sarabi M, Hajabdollahi F, et al. Gene therapy: A promising approach for breast cancer treatment. Cell Biochem Funct. 2022;40(1):28-48.
6. Kesheh MM, Mahmoudvand S, Shokri S. Long noncoding RNAs in respiratory viruses: A review. Rev Med Virol. 2022;32(2):e2275.
7. Zhu P, Liu B, Fan Z. Noncoding RNAs in tumorigenesis and tumor therapy. Fundam Res. 2023;3(5):692-706.
8. Hu J, Peng F, Qiu X, Yang J, Li J, Shen C, et al. NR2F1-AS1: A Functional Long Noncoding RNA in Tumorigenesis. Curr Med Chem. 2023;30(37):4266-76.
9. Song J, Tang Y, Song F. Lnc‑RGS5 sponges miR‑542‑5p to promote FoxM1/VEGFA signaling and breast cancer cell proliferation. Int J Oncol. 2023;63(4).
10. Yang M, Lu Y, Piao W, Jin H. The Translational Regulation in mTOR Pathway. Biomolecules. 2022;12(6):802.
11. Li J, Zhang J, Jin L, Deng H, Wu J. Silencing lnc-ASAH2B-2 Inhibits Breast Cancer Cell Growth via the mTOR Pathway. Anticancer Res. 2018;38(6):3427-34.
12. Lee JH, Massague J. TGF-beta in developmental and fibrogenic EMTs. Semin Cancer Biol. 2022;86(Pt 2):136-45.
13. Yu XY, Sun Q, Zhang YM, Zou L, Zhao YY. TGF-beta/Smad Signaling Pathway in Tubulointerstitial Fibrosis. Front Pharmacol. 2022;13:860588.
14. Li Z, Dong M, Fan D, Hou P, Li H, Liu L, et al. LncRNA ANCR down-regulation promotes TGF-beta-induced EMT and metastasis in breast cancer. Oncotarget. 2017;8(40):67329-43.
15. Wu ZJ, Li Y, Wu YZ, Wang Y, Nian WQ, Wang LL, et al. Long non-coding RNA CCAT2 promotes the breast cancer growth and metastasis by regulating TGF-beta signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(4):706-14.
16. Pourramezan Z, Attar FA, Yusefpour M, Azizi M, Oloomi M. Circulating LncRNAs landscape as potential biomarkers in breast cancer. Cancer Rep (Hoboken). 2023;6(2):e1722.
17. Li J, Huang Y, Deng X, Luo M, Wang X, Hu H, et al. Long noncoding RNA H19 promotes transforming growth factor-beta-induced epithelial-mesenchymal transition by acting as a competing endogenous RNA of miR-370-3p in ovarian cancer cells. Onco Targets Ther. 2018;11:427-40.
18. Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, et al. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015;6(30):29209-23.
19. Richards EJ, Zhang G, Li ZP, Permuth-Wey J, Challa S, Li Y, et al. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) beta: LncRNA-hit-mediated TGFbeta-induced epithelial to mesenchymal transition in mammary epithelia. J Biol Chem. 2015;290(11):6857-67.
20. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015;6(13):11652-63.
21. Rim EY, Clevers H, Nusse R. The Wnt Pathway: From Signaling Mechanisms to Synthetic Modulators. Annu Rev Biochem. 2022;91:571-98.
22. Xiao C, Wu CH, Hu HZ. LncRNA UCA1 promotes epithelial-mesenchymal transition (EMT) of breast cancer cells via enhancing Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2016;20(13):2819-24.
23. Huan J, Xing L, Lin Q, Xui H, Qin X. Long noncoding RNA CRNDE activates Wnt/beta-catenin signaling pathway through acting as a molecular sponge of microRNA-136 in human breast cancer. Am J Transl Res. 2017;9(4):1977-89.
24. Cai Y, He J, Zhang D. Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. Onco Targets Ther. 2015;8:2657-64.
25. Li X, Yang J, Ni R, Chen J, Zhou Y, Song H, et al. Hypoxia-induced lncRNA RBM5-AS1 promotes tumorigenesis via activating Wnt/beta-catenin signaling in breast cancer. Cell Death Dis. 2022;13(2):95.
26. Li FL, Guan KL. The two sides of Hippo pathway in cancer. Semin Cancer Biol. 2022;85:33-42.
27. Wang M, Dai M, Wang D, Tang T, Xiong F, Xiang B, et al. The long noncoding RNA AATBC promotes breast cancer migration and invasion by interacting with YBX1 and activating the YAP1/Hippo signaling pathway. Cancer Lett. 2021;512:60-72.
28. Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, et al. The JAK-STAT pathway at 30: Much learned, much more to do. Cell. 2022;185(21):3857-76.
29. Hjazi A, Obaid RF, Ali SS, Abdullaev B, Alsaab HO, Huldani H, et al. The cross-talk between LncRNAs and JAK-STAT signaling pathway in cancer. Pathol Res Pract. 2023;248:154657.
30. Zhang Y, Li Z, Chen M, Chen H, Zhong Q, Liang L, et al. lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer. Breast Cancer. 2020;27(4):573-85.
31. Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017;127(12):4498-515.
32. Chisholm KM, Wan Y, Li R, Montgomery KD, Chang HY, West RB. Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma. PLoS One. 2012;7(10):e47998.
33. Shi Y, Huang Q, Kong X, Zhao R, Chen X, Zhai Y, et al. Current Knowledge of Long Non-Coding RNA HOTAIR in Breast Cancer Progression and Its Application. Life (Basel). 2021;11(6).
34. Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, et al. MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells. 2014;32(11):2858-68.
35. Asadi M, Taghizadeh S, Kaviani E, Vakili O, Taheri-Anganeh M, Tahamtan M, et al. Caspase-3: Structure, function, and biotechnological aspects. Biotechnol Appl Biochem. 2022;69(4):1633-45.
36. Chen DQ, Zheng XD, Cao Y, He XD, Nian WQ, Zeng XH, et al. Long non-coding RNA LINC00628 suppresses the growth and metastasis and promotes cell apoptosis in breast cancer. Eur Rev Med Pharmacol Sci. 2017;21(2):275-83.
37. Li T, Liu Y, Xiao H, Xu G. Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer. Breast Cancer. 2017;24(4):535-43.
38. Liao XH, Wang JG, Li LY, Zhou DM, Ren KH, Jin YT, et al. Long intergenic non-coding RNA APOC1P1-3 inhibits apoptosis by decreasing alpha-tubulin acetylation in breast cancer. Cell Death Dis. 2016;7(5):e2236.
39. Jandick NA, Kirner N, Miller CL. Mammalian orthoreovirus infection in human epidermal growth factor receptor 2 positive (HER2+) breast cancer cells. bioRxiv. 2023:2023.05. 10.540250.
40. Sas‐Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, et al. LIMT is a novel metastasis inhibiting lnc RNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO molecular medicine. 2016;8(9):1052-64.
41. Schlein LJ, Thamm DH. Review: NF-kB activation in canine cancer. Vet Pathol. 2022;59(5):724-32.
42. Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, et al. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015;27(3):370-81.
43. Marvalim C, Datta A, Lee SC. Role of p53 in breast cancer progression: An insight into p53 targeted therapy. Theranostics. 2023;13(4):1421-42.
44. Yu Y, Lv F, Liang D, Yang Q, Zhang B, Lin H, et al. HOTAIR may regulate proliferation, apoptosis, migration and invasion of MCF-7 cells through regulating the P53/Akt/JNK signaling pathway. Biomed Pharmacother. 2017;90:555-61.
45. Liang Y, Li Y, Song X, Zhang N, Sang Y, Zhang H, et al. Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. Cancer Biol Ther. 2018;19(2):120-31.
46. Chen R, Liu Y, Zhuang H, Yang B, Hei K, Xiao M, et al. Quantitative proteomics reveals that long non-coding RNA MALAT1 interacts with DBC1 to regulate p53 acetylation. Nucleic Acids Res. 2017;45(17):9947-59.
47. Cerma K, Piacentini F, Moscetti L, Barbolini M, Canino F, Tornincasa A, et al. Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. Biomedicines. 2023;11(1).
48. Zhang CY, Yu MS, Li X, Zhang Z, Han CR, Yan B. Overexpression of long non-coding RNA MEG3 suppresses breast cancer cell proliferation, invasion, and angiogenesis through AKT pathway. Tumour Biol. 2017;39(6):1010428317701311.
49. Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang G, et al. Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. Int J Clin Exp Pathol. 2015;8(5):4881-91.
50. Chen S, Wang Y, Zhang JH, Xia QJ, Sun Q, Li ZK, et al. Long non-coding RNA PTENP1 inhibits proliferation and migration of breast cancer cells via AKT and MAPK signaling pathways. Oncol Lett. 2017;14(4):4659-62.
51. Zhan XJ, Wang R, Kuang XR, Zhou JY, Hu XL. Elevated expression of myosin VI contributes to breast cancer progression via MAPK/ERK signaling pathway. Cell Signal. 2023;106:110633.
52. Peng WX, Huang JG, Yang L, Gong AH, Mo YY. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer. Mol Cancer. 2017;16(1):161.
53. Wang L, Li J, Zhao H, Hu J, Ping Y, Li F, et al. Identifying the crosstalk of dysfunctional pathways mediated by lncRNAs in breast cancer subtypes. Mol Biosyst. 2016;12(3):711-20.
54. Gao FY, Li XT, Xu K, Wang RT, Guan XX. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun Signal. 2023;21(1):28.
55. Mirmazhari SP, Abdi MJ, Mosadeghrad AH, Bonab RA, Babadi AA, Rigi G, et al. Unraveling the Complex Interplay between lncRNAs and Myc in Breast Cancer. 2023.
56. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, et al. lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. Cancer cell. 2018;33(4):706-20. e9.
57. Wang O, Yang F, Liu Y, Lv L, Ma R, Chen C, et al. C-MYC-induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer. Am J Transl Res. 2017;9(2):533-45.
58. Tamang S, Acharya V, Roy D, Sharma R, Aryaa A, Sharma U, et al. SNHG12: An LncRNA as a Potential Therapeutic Target and Biomarker for Human Cancer. Front Oncol. 2019;9:901.
59. Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35(21):2746-55.
60. Wang S, Ke H, Zhang H, Ma Y, Ao L, Zou L, et al. LncRNA MIR100HG promotes cell proliferation in triple-negative breast cancer through triplex formation with p27 loci. Cell Death Dis. 2018;9(8):805.
61. Wood JL, Zhang C, Mathews ER, Tang C, Franks AE. Microbial community dynamics in the rhizosphere of a cadmium hyper-accumulator. Sci Rep. 2016;6:36067.
| Files | ||
| Issue | Vol 6, No 3 (2023) | |
| Section | Review Article | |
| DOI | https://doi.org/10.18502/igj.v6i3.16573 | |
| Keywords | ||
| Breast Cancer Immunology Long-Non-Coding RNA Signaling Pathway | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Lotfi M, Mahmoudian-Sani M-R, Saeedi-Sarqaleh M, Shojaei-Moghaddam F, Saadati-Maleki H, Karimzadeh-Soureshjani E, Saadi R, Saeedi-Boroujeni A. Long Non-Coding RNAs (lncRNA) Are Key Factors in the Complex Puzzle of Breast Cancer Immunopathogenesis: A Review Study. Immunol Genet J. 2023;6(3):91-102.
